Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    87,233.20
    -1,011.73 (-1.15%)
     

  • CMC Crypto 200

    1,327.45
    -69.08 (-4.95%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on BIIB, CYTK, ISIS and SRPT

ACCESSWIRE

The Biotech Investor has continued to show impressive growth in 2013. On Wednesday, the Nasdaq Biotechnology Index reached a record high and has gained approximately 43.0 percent year-to-date. Additionally the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) and the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) have posted gains of 47.0 percent and 43.0 percent, respectively, this year. The major catalyst for the Biotech sector has been FDA approvals. Bringing a drug to market will easily send shares skyrocketing, while a failure could be devastating. Through the first half of 2013 there have been 13 new approvals from the FDA.

Biogen Idec Inc. (NASDAQ:BIIB - News) shares traded in the range of $226.02 to $231.72 Thursday before settling to close at $227.70, a decrease of 1.25 percent. The stock appears to be facing some resistance at the $228.00 and $234.69 levels with some support at $223.33. Shares of Biogen Idec have gained approximately 55.0 percent in 2013.

More information on Biogen Idec and access to the free equity report can be found at:
www.WallStreetFundamentals.com/BIIB

Cytokinetics, Inc. (NASDAQ:CYTK - News) shares traded in the range of $8.13 to $8.62 Thursday before settling to close at $8.43, an increase of 3.06 percent. The stock appears to be facing some resistance at the $8.71 and $9.80 levels with some support at $7.68. Shares of Cytokinetics have gained approximately 110.0 percent in 2013.

ADVERTISEMENT

More information on Cytokinetics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CYTK

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS - News) shares traded in the range of $27.78 to $29.55 Thursday before settling to close at $28.47, a decrease of 2.27 percent. The stock appears to be facing some resistance at the $29.17 and $33.97 levels with some support at $26.90. Shares of ISIS Pharmaceuticals have gained approximately 170.0 percent in 2013.

More information on ISIS Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ISIS

Sarepta Therapeutics Inc. (NASDAQ:SRPT - News) shares traded in the range of $35.90 to $36.73 Thursday before settling to close at $36.42, an increase of 0.30 percent. The stock appears to be facing some resistance at the $36.92 and $38.90 levels with some support at $35.83. Shares of Sarepta Therapeutics have gained approximately 41.0 percent in 2013.

More information on Sarepta Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SRPT

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com